2011 - IPITA - Prague


This page contains exclusive content for the member of the following sections: TTS, IPITA. Log in to view.

Parallel session 7 – Open mini-oral presentations Topic: Islet transplantation: Technical aspects

7.7 - Designing polymer nanofiber scaffolds loaded with proangiogenic and immune modulatory compounds for islet transplant

Presenter: K., Brayman, Charlottesville, USA
Authors: K. Brayman, D. Bowers, P. Chhabra, L. Langman, E. Botchwey


Designing polymer nanofiber scaffolds loaded with proangiogenic and immune modulatory compounds for islet transplant

K. Brayman1, D. Bowers2, P. Chhabra1, L. Langman1, E. Botchwey2
1 University of Virginia, Surgery, Transplant Division, Charlottesville, USA; 2 University of Virginia, Biomedical Engineering, Charlottesville, USA

Objectives: Alternate islet transplant sites must be pre-vascularized or very quickly vascularized following transplant in order to prevent hypoxia induced necrosis. The local release of the S1P analog pro-drug FTY720 (fingolimod, Gilenya), can induce microvascular remodeling. We are investigating the ability of nanofiber scaffolds loaded with FTY720 to modulate the process of angiogenesis and inflammation as well as provide physical cues that mimic the extracellular matrix.

Materials and Methods: Nanofibers are electrospun from polymer solutions of PLAGA or PLAGA/PCL with and without FTY720. Islets are assessed for viability (Propidium Iodide and Fluorescein Diacetate staining) and function (response to 28mM and 2.8mM glucose). Microvascular remodeling is assessed by automated image analysis of intravital light microscopy images obtained from dorsal skinfold window chambers.

Results: Image analysis of repeated measures of microvessel metrics show significant differences between diabetic and non-diabetic animals within 7 days of implant in response to FTY720 local release (p<0.05). Islets cultured with nanofibers for 48 hours show a reduced viability (45% fibers verses 70% for controls), however the addition of FTY720 improves the viability to at least that of untreated islets (76%). No significant differences in Stimulation Index have been found (1.85 controls verses 2.0 fibers). Preliminary data from in vivo studies suggest that local release of FTY720 may reduce the rejection process in allotransplant models.

Conclusions: A polymer nanofiber pocket provides a device in which islets can be transplanted in alternate sites. The porous nature of the nanofibers will allow blood vessels to penetrate the pocket to reform the important intraislet vasculature. The manipulability of the islet engraftment process using local release of factors, such as FTY720, from the biodegradable polymers makes an attractive system where a strict immune barrier may not be required. Further animal studies, including xenogenic transplants are planned.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada